Accutar Biotech

Accutar Biotech (legally Accutar Biotechnology Inc.) is a U.S.-based biotechnology company that applies artificial intelligence to drug discovery. Its stated philosophy is to build a data-driven foundation for explaining the physical and chemical nature of biological systems, and it uses a hybrid workflow in which computational drug design is followed by wet-lab experimental validation, with the aim of reducing the time and cost of traditional drug discovery [0][2]. The company describes its proprietary platform as leveraging a universal force-field-based modeling methodology and states it has reduced average preclinical drug discovery time to approximately one year [1].

The company markets a set of named AI solutions and tools, including ChemiRise, Orbital, Virtual Screen, Intelligent-SAR, Chemi-Net, InsightOne and GenusOne, alongside an internal drug pipeline [0]. Its clinical activity described in public materials centers on oncology: lead candidate AC699 is in development for ER+/HER2- breast cancer, with Phase 1 monotherapy data presented at ASCO in June 2024 and FDA Fast Track designation announced in August 2024 [0]. Leadership includes founder and CEO Dr. Jie Fan, CSO Dr. Wei He, Chief Discovery Officer and Head of Chemistry Dr. Yimin Qian, CTO Xiangyan Sun, VP of Finance Jiaqi Ren, and Chief Business Officer Aaron Feng Chen; Dr. Pasi A. Jänne is listed as an advisor [2]. A directory listing gives a Brooklyn, New York address and an employee band of 1-50 [2], while a secondary-market platform lists the headquarters as Cranbury, New Jersey and a 2015 founding year [5].

Founding story

Accutar Biotech was founded by Dr. Jie Fan, who trained in biostatistics at the University of California, Berkeley and earned a doctorate in structural biology and immunology from the Weill Cornell Graduate School of Medical Sciences and Memorial Sloan Kettering Cancer Center, followed by further training with Nobel laureate Dr. Günter Blobel at Rockefeller University. Fan founded the company with Blobel's support, motivated by the goal of reforming the conventional "hit-to-lead" drug discovery process by combining computational design with experimental validation [2][3]. Forge Global lists the founding year as 2015 [5].

Business model

Accutar Biotech develops its own proprietary drug pipeline discovered on its internal AI platform and also positions its AI solutions as tools to accelerate drug discovery efforts; it has additionally entered a partnership structure with a pharmaceutical company to form a joint new company around a therapeutic area [0][1].

Traction

Lead asset AC699 produced Phase 1 monotherapy data presented at ASCO 2024 and received FDA Fast Track designation in August 2024 for ER+/HER2- breast cancer [0]. Cumulative disclosed funding exceeded $100 million by April 2021 [1] and is reported at $207.47 million in total by a secondary-market data provider [5].

Latest developments

On July 10, 2026 the company announced that China's HEC Pharm would partner with Accutar to form a NewCo targeting the underserved metastatic castration-resistant prostate cancer market [0]. Executive updates listed in 2025-2026 include Aaron Feng Chen as Chief Business Officer, Janet Hurt as SVP of Clinical Operations, and Dr. Pasi A. Jänne as an advisor [2].